Sanofi Weighs Sale of Bio-Surgery, Renal, Animal Health Units

Source: Bloomberg

Sep 25, 2015

According to Bloomberg sources, French drugmaker Sanofi is considering the disposal of its bio-surgery, renal and Merial animal health units as part of a strategic business review.

No final decision has been made and Sanofi may choose to keep the assets, sources said. An update is expected at an investor meeting in November.

Sanofi's bio-surgery business, obtained through a 2011 purchase of Genzyme Corp., has annual sales of about $223M. Sanofi acquired Merck’s 50% stake in Merial animal health in 2009. Sales are about $2.6 billion.

In July, Sanofi announced that it will adopt a simplified structure centered around five global business units. The reorg came under the control of newly hired CEO, Olivier Brandicourt, who took the wheel in April. Brandicourt has said that he will present a five-year strategic growth plan in November.

Read the Bloomberg release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments